April 19, 2019

James Kasinger
General Counsel and Secretary
CRISPR Therapeutics AG
Baarerstrasse 14
6300 Zug
Switzerland

       Re: CRISPR Therapeutics AG
           Preliminary Proxy Statement on Schedule 14A
           Filed on April 9, 2019
           File No. 001-37923

Dear Mr. Kasinger:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to these comments, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A filed on April 9, 2019

Proposal 11: Amending and Restating art. 3a of the Articles of Association
Proposal 12: Amending and Restating art. 4 of the Articles of Association
Proposal 13: Amending and Restating art. 16 of the Articles of Association
Proposal 14: Amending and Restating art. 17 of the Articles of Association,
page 64

1.    Please expand your disclosure to briefly state the reasons for and the
general effects of the
      proposed amendments to your Articles of Association. Refer to Item 19 of
Schedule
      14A. With respect to Proposal 11, please also disclose whether you have
any plans,
      agreements, arrangements or understandings, whether written or oral,
relating to the
      issuance of the additional authorized common shares that will become
available as a result
      of the proposed amendment. If none, so state. Refer to Note A to Schedule
14A.

       We remind you that the company and its management are responsible for
the accuracy
 James Kasinger
CRISPR Therapeutics AG
April 19, 2019
Page 2

and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Please contact Christine Westbrook at 202-551-5019 or Erin Jaskot at
202-551-3442 with
any other questions.



FirstName LastNameJames Kasinger                          Sincerely,
Comapany NameCRISPR Therapeutics AG
                                                          Division of
Corporation Finance
April 19, 2019 Page 2                                     Office of Healthcare
& Insurance
FirstName LastName